Discordant effects of rosiglitazone on novel inflammatory biomarkers

American Heart Journal

Volumn 165, Issue 4, 2013, Pages 609-614

  Gada, Elan ^a   Owens, Andrew W ^a   Gore, M Odette ^a   See, Raphael ^b   Abdullah, Shuaib M ^a,c   Ayers, Colby R ^a   Rohatgi, Anand ^a   Khera, Amit ^a   De Lemos, James A ^a   McGuire, Darren K ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCL23 CHEMOKINE; CHEMOKINE; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; GELATINASE B; LYMPHOTOXIN BETA RECEPTOR; PEPTIDOGLYCAN RECOGNITION PROTEIN; PEPTIDOGLYCAN RECOGNITION PROTEIN 1; PLACEBO; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CYTOKINES; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPOGLYCEMIC AGENTS; LYMPHOTOXIN BETA RECEPTOR; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PILOT PROJECTS; THIAZOLIDINEDIONES;

EID: 84875476553     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.01.006     Document Type: Article

References (45)

1. C.B. Patel, J.A. De Lemos, and K.L. Wyne Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of ppar gamma agonism Diab Vasc Dis Res 3 2006 65 71
2. D.K. McGuire, and S.E. Inzucchi New drugs for the treatment of diabetes mellitus: part I: thiazolidinediones and their evolving cardiovascular implications Circulation 117 2008 440 449
3. M. Hanefeld, N. Marx, and A. Pfutzner Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT study J Am Coll Cardiol 49 2007 290 297
4. N. Marx, A. Imhof, and J. Froehlich Effect of rosiglitazone treatment on soluble cd40l in patients with type 2 diabetes and coronary artery disease Circulation 107 2003 1954 1957
5. S.M. Haffner, A.S. Greenberg, and W.M. Weston Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus Circulation 106 2002 679 684
6. H. Koshiyama, D. Shimono, and N. Kuwamura Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes J Clin Endocrinol Metab 86 2001 3452 3456
7. M.R. Langenfeld, T. Forst, and C. Hohberg Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study Circulation 111 2005 2525 2531
8. T. Mazzone, P.M. Meyer, and S.B. Feinstein Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial JAMA 296 2006 2572 2581
9. M. Mizoguchi, N. Tahara, and A. Tahara Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta JACC Cardiovasc Imaging 4 2011 1110 1118
10. T. Takagi, A. Yamamuro, and K. Tamita Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study Am Heart J 146 2003 E5
11. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471
12. A. Rohatgi, and D.K. McGuire Effects of the thiazolidinedione medications on micro- and macrovascular complications in patients with diabetes - update 2008 Cardiovasc Drugs Ther 22 2008 233 240
13. R.G. Victor, R.W. Haley, and D.L. Willett The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health Am J Cardiol 93 2004 1473 1480
14. A.W. Owens, S. Matulevicius, and A. Rohatgi Circulating lymphotoxin beta receptor and atherosclerosis: observations from the Dallas Heart Study Atherosclerosis 212 2010 601 606
15. A. Rohatgi, C.R. Ayers, and A. Khera The association between peptidoglycan recognition protein-1 and coronary and peripheral atherosclerosis: observations from the Dallas Heart Study Atherosclerosis 203 2009 569 575
16. L. Castillo, A. Rohatgi, and C.R. Ayers Associations of four circulating chemokines with multiple atherosclerosis phenotypes in a large population-based sample: Results from the Dallas Heart Study J Interferon Cytokine Res 30 2010 339 347
17. J.B. Lindsey, J.A. de Lemos, and F. Cipollone Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study Diabetes Care 32 2009 1218 1220
18. D.K. McGuire, R. See, and S.M. Abdullah The effect of rosiglitazone on integrated cardiovascular performance, cardiac structure, function and myocardial triglyceride: trial design and rationale Diab Vasc Dis Res 6 2009 43 50
19. D.K. McGuire, S.M. Abdullah, and R. See Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function Eur Heart J 31 2010 2262 2270
20. American Diabetes Association Standards of medical care in diabetes - 2008 Diabetes Care 31 Suppl. 1 2008 S12 S54
21. A. Rohatgi, A.W. Owens, and A. Khera Differential associations between soluble cellular adhesion molecules and atherosclerosis in the Dallas Heart Study: a distinct role for soluble endothelial cell-selective adhesion molecule Arterioscler Thromb Vasc Biol 29 2009 1684 1690
22. J.R. Romero, R.S. Vasan, and A.S. Beiser Association of carotid artery atherosclerosis with circulating biomarkers of extracellular matrix remodeling: the Framingham Offspring Study J Stroke Cerebrovasc Dis 17 2008 412 417
23. K. Schneider, K.G. Potter, and C.F. Ware Lymphotoxin and light signaling pathways and target genes Immunol Rev 202 2004 49 66
24. J.L. Gommerman, and J.L. Browning Lymphotoxin/light, lymphoid microenvironments and autoimmune disease Nat Rev Immunol 3 2003 642 655
25. M.A. Houtkamp, O.J. de Boer, and C.M. van der Loos Adventitial infiltrates associated with advanced atherosclerotic plaques: structural organization suggests generation of local humoral immune responses J Pathol 193 2001 263 269
26. I.A. Schrijver, M.J. Melief, and P.P. Tak Antigen-presenting cells containing bacterial peptidoglycan in synovial tissues of rheumatoid arthritis patients coexpress costimulatory molecules and cytokines Arthritis Rheum 43 2000 2160 2168
27. I.A. Schrijver, M. van Meurs, and M.J. Melief Bacterial peptidoglycan and immune reactivity in the central nervous system in multiple sclerosis Brain 124 2001 1544 1554
28. L. Lehtonen, E. Eerola, and P. Toivanen Muramic acid in human peripheral blood leucocytes in different age groups Eur J Clin Invest 27 1997 791 792
29. J.D. Laman, A.H. Schoneveld, and F.L. Moll Significance of peptidoglycan, a proinflammatory bacterial antigen in atherosclerotic arteries and its association with vulnerable plaques Am J Cardiol 90 2002 119 123
30. J.H. Cho, I.P. Fraser, and K. Fukase Human peptidoglycan recognition protein s is an effector of neutrophil-mediated innate immunity Blood 106 2005 2551 2558
31. C. Liu, E. Gelius, and G. Liu Mammalian peptidoglycan recognition protein binds peptidoglycan with high affinity, is expressed in neutrophils, and inhibits bacterial growth J Biol Chem 275 2000 24490 24499
32. J.B. Sims, J.A. de Lemos, and P. Maewal Urinary tract infection in patients with acute coronary syndrome: a potential systemic inflammatory connection Am Heart J 149 2005 1062 1065
33. L.L. Humphrey, R. Fu, and D.I. Buckley Periodontal disease and coronary heart disease incidence: a systematic review and meta-analysis J Gen Intern Med 23 2008 2079 2086
34. J. Danesh Coronary heart disease, helicobacter pylori, dental disease, chlamydia pneumoniae, and cytomegalovirus: meta-analyses of prospective studies Am Heart J 138 1999 S434 S437
35. U. Forssmann, M.B. Delgado, and M. Uguccioni Ckbeta8, a novel cc chemokine that predominantly acts on monocytes FEBS Lett 408 1997 211 216
36. I. Rioja, F.J. Hughes, and C.H. Sharp Potential novel biomarkers of disease activity in rheumatoid arthritis patients: Cxcl13, ccl23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor Arthritis Rheum 58 2008 2257 2267
37. J.B. Lindsey, F. Cipollone, and S.M. Abdullah Receptor for advanced glycation end-products (RAGE) and soluble rage (SRAGE): cardiovascular implications Diab Vasc Dis Res 6 2009 7 14
38. L. Park, K.G. Raman, and K.J. Lee Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products Nat Med 4 1998 1025 1031
39. L.G. Bucciarelli, T. Wendt, and W. Qu Rage blockade stabilizes established atherosclerosis in diabetic apolipoprotein e-null mice Circulation 106 2002 2827 2835
40. T. Wendt, E. Harja, and L. Bucciarelli Rage modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes Atherosclerosis 185 2006 70 77
41. C. Falcone, E. Emanuele, and A. D'Angelo Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men Arterioscler Thromb Vasc Biol 25 2005 1032 1037
42. J. Woodcock, J.M. Sharfstein, and M. Hamburg Regulatory action on rosiglitazone by the U.S. Food and drug administration N Engl J Med 363 2010 1489 1491
43. D. Cohen European regulatory body recommends suspension of rosiglitazone BMJ 341 2010 c5291
44. G. Hsiao, J. Chapman, and J.M. Ofrecio Multi-tissue, selective ppargamma modulation of insulin sensitivity and metabolic pathways in obese rats Am J Physiol Endocrinol Metab 300 2011 E164 E174
45. R.B. Goldberg, D.M. Kendall, and M.A. Deeg A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia Diabetes Care 28 2005 1547 1554